For example, in the STEP 1 trial , patients taking semaglutide lost an average of 14.9% of their body weight over 68 weeks , compared with just 2.4% in the placebo group (NEJM study)
Although there are several MRP1 inhibitors that have been investigated in preclinical and clinical studies, there are currently no MRP1 inhibitors that are approved for clinical use as chemosensitizers (Wang et al., 2021a)
Temporary Lightening of Hair and Eyes: With prolonged use, some users have reported a slight lightening of hair color or eye color, although this is temporary and uncommon
Sermorelin, acting on GHRH-R, is itself physiologically targeted to somatotrophs
Researchers should note that the aforementioned peptides are usually applied via subcutaneous injections, so injection site reactions are possible